Profil
James C.
O'Shea has been Chairman, President and Chief Executive Officer of Bioject Medical Technologies, Inc. since March 1995.
He was President and Chief Operating Officer of Biopure Corporation.
He was Executive Vice President of Marketing and Scientific Affairs for Delmed, Inc.
Ehemalige bekannte Positionen von James C. O'Shea
| Unternehmen | Position | Ende |
|---|---|---|
| BIOJECT MEDICAL TECHNOLOGIES INC. | Präsident | 31.12.2006 |
| Delmed, Inc. | Technik-/Wissenschafts-/F&E-Leiter | - |
Biopure Corp.
 Biopure Corp. Pharmaceuticals: MajorHealth Technology Biopure Corp. developed, manufactured and marketed oxygen therapeutics, a new class of pharmaceuticals that are administered intravenously to increase oxygen transport to the body's tissues. The company used patented and proprietary technology to develop and manufacture two products: Hemopure for human use, and Oxyglobin for veterinary use. It has developed Hemopure for the treatment of patients with cardiovascular ischemia. Oxyglobin, its veterinary product treated anemia in dogs, is the only oxygen therapeutic approved by the U.S. Food and Drug Administration and the European Commission. Biopure was founded in 1984 and was headquartered in Cambridge, MA. | Präsident | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 3 |
|---|---|
Bioject Medical Technologies, Inc.
 Bioject Medical Technologies, Inc. Medical SpecialtiesHealth Technology Bioject Medical Technologies, Inc. develops and manufactures needle-free injection therapy systems. Its products include Biojector 2000, Needle Free Injection System, ZetaJet, Drug Reconstitution System, and Needle-Free Vial Adapter. The company was founded in 1985 and is headquartered in Tigard, OR. | Health Technology |
Biopure Corp.
Biopure Corp. Pharmaceuticals: MajorHealth Technology Biopure Corp. developed, manufactured and marketed oxygen therapeutics, a new class of pharmaceuticals that are administered intravenously to increase oxygen transport to the body's tissues. The company used patented and proprietary technology to develop and manufacture two products: Hemopure for human use, and Oxyglobin for veterinary use. It has developed Hemopure for the treatment of patients with cardiovascular ischemia. Oxyglobin, its veterinary product treated anemia in dogs, is the only oxygen therapeutic approved by the U.S. Food and Drug Administration and the European Commission. Biopure was founded in 1984 and was headquartered in Cambridge, MA. | Health Technology |
| Delmed, Inc. | Health Technology |
